Cabozantinib is being developed for the treatment of progressive differentiated thyroid cancer (DTC). Thyroid cancer is rare, and DTC is the most common type of this. It is usually found by a hard lump on the neck that does not move and may grow. It can cause a sore throat, neck pain, hoarseness, and difficulty swallowing and/or breathing. People with DTC have limited options if their previous treatment has been unsuccessful.
Cabozantinib for treating differentiated thyroid cancer
Cabozantinib is being developed for the treatment of progressive differentiated thyroid cancer (DTC). Thyroid cancer is rare, and DTC is the most common type of this.
Interventions:
Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)
Indications:
Differentiated thyroid cancer (DTC)
Therapeutic Areas:
Head and Neck Cancer
Year:
2021